Amplifon (AMP) M&A announcement summary

Deal rationale and strategic fit

• Creates a global, vertically integrated leader in hearing care and audiology, combining advanced product innovation, clinical expertise, and patient insights.

• Leverages GN Hearing's technology and Amplifon's clinical know-how to elevate industry standards and accelerate innovation cycles.

• Addresses growing global demand for advanced hearing solutions, supported by demographic and technological trends.

• Unlocks growth potential through scale, innovation, and expanded market reach, especially in the US and Europe.

• Strong cultural alignment and complementary business models minimize integration risk and preserve brand identity.

Financial terms and conditions

• Total consideration is approximately €2.3 billion: €1.69 billion in cash and 56 million newly issued shares.

• GN Hearing valued at €2.3 billion on a cash-free, debt-free basis; GN will hold a 15–16% stake and appoint a board member.

• Cash component fully funded by a committed bridge facility, to be refinanced via debt and up to €0.75 billion equity/equity-linked raise.

• Pro forma net debt/EBITDA expected at ~3x at closing, reducing with synergies; rapid deleveraging planned.

• Transaction unanimously approved by both Boards; controlling and long-term shareholders committed to participate in the equity raise.

Synergies and expected cost savings

• Identified run-rate EBITDA synergies of €60–80 million by 2029, mainly from insourcing hearing aid production.

• One-off integration costs estimated at €80 million over 2–3 years post-closing.

• Additional upside potential from manufacturing, procurement, working capital, CapEx efficiencies, and future revenue synergies.

• Synergies considered highly executable with clear implementation plans and limited delivery risk.